Antifibrotic synergy between phosphodiesterase type 5 inhibitors and selective oestrogen receptor modulators in Peyronie’s disease models by Ilg, Marcus M. et al.
E U RO P E AN URO L OGY 7 5 ( 2 019 ) 3 2 9 – 3 4 0
ava i lable at www.sciencedirect .com
journal homepage: www.europeanurology.comSexual Medicine
Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors
and Selective Oestrogen Receptor Modulators in Peyronie's
Disease ModelsMarcus M. Ilg a, Marta Mateus a, William J. Stebbeds b, Uros Milenkovic c, Nim Christopher d,
Asif Muneer d,e,f [17_TD$DIFF], Maarten Albersen c, David J. Ralph d,f, Selim Cellek a,*
aAnglia Ruskin University, Chelmsford, UK; bCranfield University, UK; cKU Leuven, Leuven, Belgium; dUniversity College London Hospital, London, UK;
eNIHR Biomedical Research Centre, University College London Hospital, London, UK; fUniversity College London, London, UKArticle info
Article history:
Accepted October 4, 2018
Associate Editor:
Jean-Nicolas Cornu
Keywords:
Peyronie's disease
Fibroblast
Myofibroblast
Fibrosis
Fibroproliferative
Phosphodiesterase type
5 inhibitor
Oestrogen receptor modulator
Tunica albuginea
Phenotypic screening
Abstract
Background: Peyronie's disease (PD) is a fibrotic disorder of the penile tunica albuginea,
characterised by the formation of a localised fibrous plaque that can lead to deformity
and erectile dysfunction. Nonsurgical therapeutic options for PD are limited in efficacy
and safety. Myofibroblasts are key cells in the pathogenesis of PD, and inhibition of
myofibroblast transformation has been suggested as a therapeutic option.
Objective: To identify potential drugs using a novel phenotypic assay and then to test
them using in vitro and in vivo models of PD.
Design, setting, and participants: We have developed and validated a phenotypic
screening assay that measures myoﬁbroblast transformation, by which we tested
21 compounds that were suggested to be efﬁcacious in treating PD. The successful hits
from this assay were further tested using in vitro and in vivo models of PD.
Results and limitations: Thenewassaywas able to detect transforming growth factor-b1–
inducedmyoﬁbroblast transformation.Using this assay,phosphodiesterase type5 inhibitors
(PDE5i) and selective oestrogen receptor modulators (SERMs) were identiﬁed to signiﬁ-
cantly inhibit myoﬁbroblast transformation. A PDE5i (vardenaﬁl) and an SERM (tamoxifen)
inhibited myoﬁbroblast transformation, collagen gel contraction, and extracellular matrix
production in a synergistic fashion. In a rat model of PD, the antiﬁbrotic effect of the
combinationofvardenaﬁl andtamoxifenwasgreater thanthatofeachdrugalone.This study
is limited by not providing a molecular mechanism for the proposed synergy.
Conclusions: This is the ﬁrst demonstration of a synergistic activity between a PDE5i
and an SERM discovered through a phenotypic screening approach. Future clinical trials
using a combination of these drugs should be considered during the active phase of PD,
given the early evidence of beneﬁt in both in vitro and in vivo models.
Patient summary: This report suggests that the combination of a phosphodiesterase
type 5 inhibitor and a selective oestrogen receptor modulator may be efﬁcacious in
treating Peyronie's disease in its active phase.
© 2018 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).* Corresponding author. Medical Technology Research Centre, Faculty of [19_TD$DIFF]Health, [20_TD$DIFF]Education, Medicine
and Social Care, Anglia Ruskin University, Bishop Hall Lane, Chelmsford, Essex, CM1 1SQ, UK.
llek@anglia.ac.uk (S. Cellek).E-mail address: selim.cehttps://doi.org/10.1016/j.eururo.2018.10.014
0302-2838/© 2018 The Author(s). Published by Elsevier B.V. on behalf of Eur
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncopean Association of Urology. This is an open access article
-nd/4.0/).
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Peyronie's disease (PD) is a fibrotic disorder characterised
by the formation of a fibrous plaque in the connective
tissue surrounding the penile erectile tissue, the tunica
albuginea (TA). It is a benign condition of unknown
aetiology characterised by the formation of localised
fibrous plaques, resulting in a penile deformity, manifest-
ing as a curvature, indentation, or shortening during
erection. The disease has been shown to be prevalent,
especially as men get older [1], and affects quality of life,
principally through pain during erection, erectile dysfunc-
tion, loss of penetrative ability during intercourse, and
associated psychological stress [2,3]. Despite the progress
in understanding the pathophysiology of PD, there is
currently a lack of efficacious medical therapies for PD,
with surgery or collagenase injections [4] being the main
treatment options. Although the surgical outcomes fol-
lowing penile straightening are well documented, surgery
is invasive, costly, and frequently detrimental to penile size
and erectile function [5].
Myofibroblasts have the features of both fibroblasts and
smoothmuscle cells, and are characterised by the presence
of alpha-smooth muscle actin (a-SMA)-positive cyto-
plasmic fibres. These actin fibres contribute to the
contractile ability of these cells [6]. Although various
progenitor cells for myofibroblasts have been suggested
[7], they most often differentiate from locally residing
fibroblasts through normal wound healing signalling,
particularly transforming growth factor-b1 (TGF-b1)
[8]. Myofibroblasts have been shown to play vital and
ubiquitous roles in both normal wound healing and
fibrosis. Most important functions include production
and remodelling of extracellular matrix (ECM) protein
[6,9], and secretion of profibrotic and proinflammatory
cytokines [9]. These cells have been shown to be present in
liver [10], lung [11], and kidney [12] fibrosis as well as in PD
plaques [13,14]. It is therefore generally agreed that
myofibroblasts play a critical role in the pathophysiology
of fibrosis. Since the inhibition of myofibroblast transfor-
mation has been shown to be effective in preventing
fibrosis [15], we aimed to identify whether compounds
that are suggested for the treatment of PD can inhibit
myofibroblast formation using a phenotypic screening
assay. Here, we report the development of such a
phenotypic screening assay through which we identified
two classes of drugs, phosphodiesterase type 5 inhibitors
(PDE5i) and selective oestrogen receptor modulators
(SERM), which were shown to synergise in both in vitro
and in vivo studies.
We first developed a phenotypic screening assay that is
capable of reproducibly measuring transformation of
human primary TA-derived fibroblasts to myofibroblasts
in a high-throughput format. We then tested 21 com-
pounds/drugs that have been suggested to be efficacious in
in vitro, in vivo animal, and human studies of PD. We
identified two classes of drugs, PDE5i and SERMs, from that
screen and further tested them alone or in combination in in
vitro and in vivo models of PD.2. Patients and methods
2.1. Acquisition of TA samples and isolation of fibroblasts
TA tissue samples were collected from patients undergoing surgery at
University College London Hospital (UCLH), London, UK, for penile
cancer or PD. All patients gave fully informed written consent to the
study. This study was approved by independent research ethics
committees (NRES Committee East of England 12/EE/0170 and NRES
Committee North of Scotland 15/NS/0051). PD plaque tissue was
obtained from patients with chronic PD undergoing a Lue procedure
(plaque incision and grafting). Plaque tissue would have otherwise been
discarded. Nonplaque TA was obtained from PD patients undergoing a
Nesbit procedure whereby nonﬁbrotic TA tissue was excised from the
opposite side of the plaque. TA tissue samples from patients with penile
cancer were taken from the proximal side away from the tumour, with
the tumour showing negative margins on histological examination.
Tissue samples were carefully dissected to ensure that all cavernosal
tissue was removed from the TA. To establish ﬁbroblast cultures, TA
fragments were seeded in six-well tissue culture plates ([2_TD$DIFF] isher Scientiﬁc, [22_TD$DIFF]
Loughborough, United Kingdom) as described previously [16]. The tissue
pieces were incubated in DMEM-F12 (GIBCO, Invitrogen, [23_TD$DIFF]Waltham,
Massachusetts, United States) containing 10% FCS (Fisher Scientiﬁc) and
1%penicillin-streptomycin (GIBCO, Invitrogen)at37 Cand5%CO2, for 5–7
d. Tissue fragmentswere carefully removedusing forceps uponoutgrowth
of cells. Passages 2–4 were used for the rest of the experiments.
2.2. In-cell enzyme-linked immunosorbent assay
Cells were seeded onto 96-well, optical, ﬂat-bottom, black microplates
(Nunc, Fisher Scientiﬁc) at 5  103[18_TD$DIFF] cells/well. After overnight attachment,
they were incubatedwith or without 10 ng/ml TGF-b1 for 72 h. The cells
were then ﬁxed using 4% paraformaldehyde, and blocked with 10%
donkey serum and 0.1% Triton X-100 in phosphate-buffered saline (PBS).
The cells were then incubated with anti–a-SMA antibody (1:3000;
Sigma-Aldrich, [24_TD$DIFF]Gillingham, United Kingdom) for 2 h. Afterwards cells
were incubated with donkey antimouse secondary antibody conjugated
to an infrared dye that emits at 800 nm (1:500; IRdye 800CW; Li-COR, [25_TD$DIFF]
Cambridge, United Kingdom) and a nuclear counterstain at that emits at
700 nm (1:1000; DRAQ5; Biostatus, [22_TD$DIFF]Loughborough, United Kingdom) for
1 h. The plate was scanned using an infrared imaging system (Odyssey
CLx imager; LI-COR) at both 700 and 800 nm wavelengths.
2.3. Collagen gel contraction assay
A [26_TD$DIFF]cell contraction assay (CBA-201; Cell Biolabs Inc[27_TD$DIFF]., San Diego, California,
United States) was used according to the manufacturer's instructions.
Brieﬂy, 10 000 cells/well were mixed with collagen solution and DMEM
with or without 10 ng/ml TGF-b1, and then plated onto 96-well plates.
Cultures were incubated for 3 d at 37 C, at 5% CO2, and lattices were
released from the walls of the wells using a sterile spatula or needle.
Contraction of the collagen lattices was observed for 8 h and
documented using a digital camera (Canon Digital IXUS 55, 5.0 mega
pixels). Images were analysed using ImageJ software by measuring the
surface area of the contracting lattice. Contraction was calculated as
percentage of the surface of the unreleased lattice. Data are shown as
percentage of maximum contraction of vehicle control.
2.4. ECM production assay
Cells were seeded onto 96-well, optical, ﬂat-bottom, black microplates
(Nunc, Fisher Scientiﬁc) at 5  103 cells/well. After overnight attachment,
they were stimulated with or without 10 ng/ml TGF-b1 and/or
E U RO P E AN U RO LOGY 7 5 ( 2 019 ) 3 2 9 – 3 4 0 331compounds for 7 d. DRAQ5 in PBS (1:1000) was added, and cells were
incubated for 5 min at 37 C, 5% CO2, before scanning the plate to obtain
nuclear staining. Cells were then lysed using ammonium hydroxide as
described previously [17], and ECMwas ﬁxed using a solution containing
50%methanol and 7.5% acetic acid for 1 h at–20 C. Afterwards, ECMwas
stained with either Coomassie Blue (total ECM) overnight at 4 C or
primary antibodies (collagen I, Abcam, Cambridge, United Kingdom;
collagen III, Millipore; collagen V, Abcam; ﬁbronectin, Millipore[29_TD$DIFF],
Burlington, Massachusetts, United States) at 1:1000 for 1 h on a shaker,
followed by incubation with secondary antibody and scanning of the
plate using an infrared imaging system (Odyssey CLx imager; LI-COR) at
both 700 and 800 nm wavelengths. Results were normalised to the cell
number before lysis.
2.5. Animal treatment
The animal model for PD was ﬁrst described by El-Sakka et al. [18] and
modiﬁed by Bivalacqua et al. [19]. Male Sprague-Dawley rats (10–12-wk
old)were housed in a regulated environmentwith a 12-h light/dark cycle
in a standard experimental laboratory. The animals had free access to
food and water ad libitum. Fifty male Sprague-Dawley rats were divided
into ﬁve groups: A: sham (injection of vehicle citrate buffer); B: TGF-b1
injection (1mg in 100 ml citrate buffer [10 mM; Sigma-Aldrich]); C: TGF-
b1 injection + tamoxifen (5 mg/kg/d; i.p.); D: TGF-b1 injection + varde-
naﬁl (1.5 mg/kg/d; drinkingwater); and E: TGF-b1 injection + tamoxifen
+ vardenaﬁl. Treatment was initiated the next day after injury and
continued for 5 wk followed by a 48 h washout period.
2.6. Assessment of erectile function
At the end of wash-off period, under ketamine (100 mg/kg) and xylazine
(10 mg/kg) anaesthesia, the major pelvic ganglion (MPG) and cavernous
nerve (CN) were exposed bilaterally via midline laparotomy. A 25 G
butterﬂy needle, ﬁlled with 250 U/ml heparin solution, was inserted into
the proximal left corpus cavernosum and connected to a pressure
transducer for intracavernous pressure (ICP) measurement. The ICP was
recorded at a rate of 25 samples per second. A bipolar stainless-steel hook
electrodewasused to stimulate theCNdirectly via a signal generator and a
custom-built constant-current ampliﬁer generating monophasic rectan-
gular pulses with stimuli of 5, 7.5, 10, and 15 V. Depending on the
anatomical positioning and accessibility of the nerve, stimulations were
performed on either the left or the rightMPG/CN. Themaximal amplitude
of ICP during nerve electrostimulationwas calculated from baseline value
and included for statistical analysis in each animal.
Systemic blood pressure was recorded by inserting PE-50 polyeth-
ylene tubing into the right common carotid artery. After functional
testing, animals were euthanised by cervical dislocation. Following these
measurements, the penis was harvested for histological, molecular, and
transcriptional analysis.
2.7. Quantitative polymerase chain reaction
The High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems [30_TD$DIFF],
Foster City, California, United States) was used according to the
manufacturer's instructions to transcribe RNA to cDNA. One microgram
in 10 ml was added to 10 ml of the master mix for reverse transcription
(RT) for a total reaction volume of 20 ml. After RT, cDNAwas diluted 1:10
for quantitative polymerase chain reaction (qPCR). The Applied
Biosystems TaqMan Fast Advanced Master Mix was used for qPCR.
Gene-speciﬁc primer pairs for GAPDH, beta-actin, a-SMA, elastin, and
collagens I, III, and V were purchased from Applied Biosystems.
StepOnePlus Real-Time PCR System and software were used for the
experiments and data analysis. Data were analysed using the 2–DDCt[28_TD$DIFF]
method for relative quantiﬁcations.2.8. Western blot
Protein (20–30 mg) was mixed in a 1:1 ratio with 2 Laemmli buffer
(Bio-Rad[31_TD$DIFF], Hercules, California, United States) under reducing or
nonreducing conditions, and heat denatured at 95 C for 4 min. Samples
were loaded onto an Any kD Mini-PROTEAN TGX Precast Protein Gel
(Bio-Rad) along with 5 ml of a protein ladder (Bio-Rad). After the gel
electrophoresis, the transfer onto a methanol-activated PVDFmembrane
(Bio-Rad) was achieved by wet blotting for 1 h at 350 mA. Membranes
were washed before blocking the unspeciﬁc binding with 10% (w/v)
nonfat dried milk (NFDM; Marvel[32_TD$DIFF], Premier Foods, St. Albans, Hertford-
shire, United Kingdom) in 0.1% Tris-buffered saline with Tween 20 (TBS-
T) for 1 h. Primary antibodies were diluted in 5% NFDM in 0.1% TBS-T and
incubated overnight at 4 C on a shaker. Subsequently, membranes were
washed 4 with 0.1% TBS-T and blocked again. After this, the secondary
antibodies were added in a dilution of 1:3000 in 5%NFDMwith 0.1% TBS-
T and incubated for 1 h on a shaker in the dark. Four[33_TD$DIFF] 5 minutes washes
with 0.1% TBS-T[3_TD$DIFF] were followed with 5-min incubation of an enhancer
solution ([34_TD$DIFF]SuperSignal [35_TD$DIFF]West [36_TD$DIFF] ura; Thermo Fisher). Blots were visualised
using a Syngene documentation system and Genesys software.
2.9. Statistical analysis
Data analysis was performed using Microsoft Excel 2013 or GraphPad
Prism 7 software. The differences betweenmultiple groups in in vivo RT-
qPCR andWestern blot quantiﬁcation experimentswere compared using
one-wayanalysis of variance (ANOVA). The differences betweenmultiple
groups in ICP/MAP and the in vitro in-cell enzyme-linked immunosor-
bent assay (ICE) synergy experiments were compared using two-way
ANOVA. Student t test for unpaired means (two sided) was used to
compare the difference between two groups in in vitro ICC and RT-qPCR
experiments. Prior to performing this calculation, F test of equality of
variances was performed, to ensure that equal variance could be
assumed when performing Student t test. A p value of <0.05 was
considered statistically signiﬁcant. All in vitro experiments were
performed at least in triplicate (n = 9) using samples from three patients
(N = 3). Results from the nine experiments were pooled, and the mean
values and standard errors of mean were used for statistical analysis.
Eight rats were used in each group in in vivo experiments. Results from
the rats in each group were pooled, and the mean values and standard
errors of mean were used for statistical analysis.
Z factor (Z0) was used tomeasure the statistical effect size of TGF-b1–
induced myoﬁbroblast transformation, to evaluate its reproducibility,
variability, and potential use as a high-throughput screening assay. The
formula for Z0 factor is given in the Supplementary material.
3. Results
3.1. Development and validation of the phenotypic assay
We have isolated primary fibroblasts from the plaque and
nonplaque TA of patients with PD. We also isolated primary
fibroblasts from TA of patients with penile cancer as
nonfibrotic controls (Supplementary Fig. 1). The primary
fibroblasts were similar in morphology and function (as
shown by their response to TGF-b1) in all three groups:
fibroblasts derived from the plaque of PD patients,
fibroblasts derived from the nonplaque TA of PD patients,
and fibroblasts derived from the TA of patients with penile
cancer. Based on this similarity, we have utilised fibroblasts
derived from the nonplaque TA of PD patients throughout
this work since they would be more representative of
[(Fig._1)TD$FIG]
Fig. 1 – TGF-b1 induces myofibroblast transformation that can be measured by a high-throughput screening assay. Fibroblasts were exposed to TGF-b1
(10 ng/ml) for 72 h. Representative images of a-SMA staining in (A) untreated TA-derived cells and (B) TA-derived cells exposed to TGF-b1. Images were
captured at 200T magnification. Scale bars: 50mm. (C) Quantification of a-SMA–positive cells. (D) The mRNA levels of a-SMA were determined using
the 2–DDCt method. Data points were plotted as mean  SEM (N = 3 patients for each group; n = 9). (E) Representative Western blot for a-SMA content
in protein lysates from untreated cells and cells exposed to 10 ng/ml TGF-b1 for 72 h: 20mg of protein was loaded under reducing conditions. Lower
bands (35 kD) represent GAPDH loading control, higher bands (42 kD) represent a-SMA. Lane 1: protein ladder; lanes 2, 4, 6, 8: untreated TA-derived
cells; lanes 3, 5, 7, 9: cells exposed to 10 ng/ml TGF-b1. (F) Statistical validation of the ICE method. Positive controls correspond to wells exposed to
TGF-b1; negative controls correspond to wells exposed to media only. Data were normalised to nuclear dye intensity. Validation for high-throughput
screening by calculation of Z0 comparing negative with positive control wells, yielding a Z0 value of 0.89. a-SMA = alpha-smooth muscle actin;
AVG = average; Ctrl = control; ICE = in-cell enzyme-linked immunosorbent assay; Neg = negative; Pos = positive; RT-qPCR = reverse transcription
quantitative polymerase chain reaction; SEM = standard error of the mean; TA = tunica albuginea; TGF-b1 = transforming growth factor-b1.*
p < 0.05 versus negative control.
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environment. The fibroblast identity of the TA-derived cells
was validated (Supplementary Fig. 2).
Upon exposure toTGF-b1 (10 ng/ml for 72 h), we
observed a significant eight-fold increase in a-SMA
expression in both mRNA and protein levels in TA-derived
fibroblasts (Fig. 1). We then developed a phenotypic
screening assay in a 96-well plate format using ICE where
the cell viability and a-SMA protein expression can be
measured simultaneously in a reproducible manner (-
Z0 = 0.89; Fig. 1). The assay was further validated using
vehicle control and a TGF-b1 receptor antagonist(SB505124) where the cells remained viable in up to 1%
dimethyl sulphoxide and SB505124 inhibited TGF-b1–
induced myofibroblast transformation in a concentration-
dependent manner (IC50 = 0.6mM; Supplementary Fig. 3).
3.2. Hit identification
We then tested 21 compounds/drugs (Supplementary
Table 1), which have been suggested to be efficacious in
PD based on in vitro and in vivo studies and/or early-phase
clinical studies. Out of these 21 drugs, only two classes,
SERMs and PDE5i, showed significant inhibition [37_TD$DIFF]of myofi-
[(Fig._2)TD$FIG]
Fig. 2 – Concentration response curves for hits acquired from screening campaign. Effect of the (A) PDE5i vardenafil, sildenafil, and tadalafil and (B)
SERMs tamoxifen and raloxifen on TGF-b1–induced myofibroblast transformation. Cells derived from TA tissue were exposed to a range of
concentrations of PDE5i between 0.03 and 100mM in coincubation with 10 ng/ml TGF-b1 for 72 h. Data points were plotted as average SEM of the
percentage of maximum response of the a-SMA/DNA staining ratio (N = 3; n = 9). PDE5i = phosphodiesterase type 5 inhibitors; SEM = standard error of
the mean; SERM = selective oestrogen receptor modulator; TGF-b1 = transforming growth factor-b1.
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were constructed for these hits, which yielded inverse
sigmoid curves with an upper and a lower plateau without
affecting the cell viability (Fig. 2). The following molecules
were used to investigate the two classes of drugs:
vardenafil, sildenafil, and tadalafil as PDE5i (IC50 = 30, 15,
and 3.5 mM, respectively), and tamoxifen and raloxifene as
SERMs (IC50 = 11.9 and 7mM, respectively). When a PDE5i
(vardenafil) and [39_TD$DIFF]a SERM (tamoxifen) were tested in
combination, a synergy between the two drugs became
apparent (the observed inhibition was greater than the
arithmetic sum of each; Fig. 2 and Supplementary Table 2).
3.3. Functional assays
The two classes of drugs were then tested in functional
assays. Firstly, we tested their efficacy in inhibiting collagen
gel contraction as ameasure ofmyofibroblast contractility—
a characteristic function of myofibroblasts, which separates
them from fibroblasts. Collagen gels were loaded withfibroblasts, and contractionwas measured after stimulation
with TGF-b1 as described before [20,21]. Both vardenafil
and tamoxifen inhibited TGF-b1–induced contraction of
collagen at concentrations of 10 and 1 mM, respectively
(Fig. 3). Secondly, we tested the drugs’ efficacy in inhibiting
ECM protein production, which is again one of the critical
characteristic functions of myofibroblasts. Again, both
vardenafil and tamoxifen inhibited TGF-b1–induced ECM
protein production (collagens I, III, and V and fibronectin;
IC50 = 23,17, 23, and 44mMfor vardenafil, and 7, 5.3, 6.7, and
1.6 mM for tamoxifen, respectively; Fig. 4).
3.4. In vivo testing of the two hits
To elucidatewhether the drugs could also prevent fibrosis in
vivo, they were taken further to be tested in an animal
model for PD. Five weeks after TGF-b1 injection into the rat
TA, with or without treatment with vardenafil, tamoxifen,
or their combination, the rats were subjected to erectile
function measurement (ICP measurement) before harvest-
[(Fig._3)TD$FIG]
Fig. 3 – Effect of compounds on TGF-b1–induced myofibroblast collagen contraction in fibroblast-populated collagen lattices (FPCLs). (A)
Representation of the contraction of the fibroblast-populated collagen lattices. Top row: example for no contraction after release. Bottom row:
example for uniform contraction after release from the wall of the well. FPCLs were exposed to (B) 10 ng/ml TGF-b1 and various concentrations of
tamoxifen or (C) vardenafil. FPCLs were released after 72 h and contraction was observed for 8 h. Data were presented as percentage of maximum
collagen contraction compared with vehicle control (DMSO) in cells exposed to tamoxifen/vardenafil. Data points were plotted as mean  SEM (N = 3;
n = 9). DMSO = dimethyl sulphoxide; SEM = standard error of the mean; TGF-b1 = transforming growth factor-b1.* p < 0.05 versus vehicle control at the
same time point.
EU RO P E AN URO LOGY 7 5 ( 2 019 ) 3 2 9 – 3 4 0334ing the penis for molecular analysis. The ICP measurement
revealed that TGF-b1 injection led to a decrease in erectile
function by 55%, which was prevented in all treatment
groups. Treatment groups showed no significant differences
in ICP compared with the vehicle-injected group (Fig. 5).
Subsequent mRNA expression analysis of the penile tissue
harvested from the rats showed that expression of collagens
I, III, and V were significantly upregulated in the TGF-b1
injection group, but not in the vehicle or treated groups.
Treatment with vardenafil or tamoxifen therefore pre-
vented upregulation of TGF-b1–induced increase in
collagen expression. Interestingly, the combination of
vardenafil and tamoxifen acted synergistically on thedownregulation of elastin (Fig. 5). The formation of fibrosis
in response to TGF-b1 injection into the penis was further
confirmed by measuring a-SMA in the corpus cavernosum
(as a measure of loss of smooth muscle mass due to fibrotic
tissue) using Western blot and immunohistochemistry.
The results showed a significant loss of smooth muscle,
which was prevented in the treatment groups (Fig. 5).
Furthermore, immunohistochemistry using haematoxylin
and eosin and Masson's Trichrome staining showed
increased infiltration of inflammatory cells, formation of
fibrosis, and loss of smooth muscle in the TGF-b1–injected
group, effects that were prevented in the treatment groups
(Fig. 6).
[(Fig._4)TD$FIG]
Fig. 4 – Effect of compounds on TGF-b1–induced myofibroblast ECM production. Cells derived from TA tissue were exposed to a range of
concentrations of vardenafil, tamoxifen, or SB505124 in coincubation with 10 ng/ml TGF-b1 for 7 d. ECM was stained for (A) collagen I (Col I), (B)
collagen III (Col III), (C) collagen V (Col V), and (D) fibronectin after cell lysis. Data points were plotted as average SEM of the percentage of maximum
response of protein/prelysis DNA staining ratio (N = 3; n = 9). ECM = extracellular matrix; SEM = standard error of the mean; TA = tunica albuginea; TGF-
b1 = transforming growth factor-b1.
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[(Fig._5)TD$FIG]
ig. 5 – Vardenafil, tamoxifen, and their combination ameliorate penile fibrosis in an animal model for PD. (A) DICP measurement for different
timulation voltages in all the treatment groups. Intracavernous pressure (ICP) change from baseline to peak ICP (DICP). Data were plotted as mean SEM
= 7). * p< 0.05 versus vehicle-injected group. (B) mRNA levels of a-SMA (ACTA2) were determined using the 2–DDCt[5_TD$DIFF]method. Data points were plotted as
ean SEM (N = 4). * p < [6_TD$DIFF]0.05, ** p < 0.01 versus TGF-b1–injected group. (C) mRNA levels of Col I were determined using the 2–DDCt method. Data points
ere plotted as mean SEM (N = 4). * p< [6_TD$DIFF]0.05, ** p< 0.01 versus TGF-b1–injected group. (D) mRNA levels of Col III were determined using the 2–DDCt[7_TD$DIFF]
ethod. Data points were plotted as mean SEM (N = 4). [8_TD$DIFF]**** p< [9_TD$DIFF]0.0001 versus TGF-b1[10_TD$DIFF]-injected group. (E) mRNA levels of Col V were determined using the
–DDCt method. Data points were plotted as mean SEM (N = 4). *** p = 0.0001, **** p < [9_TD$DIFF]0.0001 versus TGF-b1[10_TD$DIFF]-injected group. (F) mRNA levels of elastin
LN) were determined using the 2–DDCt[11_TD$DIFF]method. Data points were plotted as mean SEM (N = 4). [12_TD$DIFF]** p < [13_TD$DIFF]0.001 vardenafil versus combination. ***
= 0.0001 versus TGF-b1[10_TD$DIFF]-injected group[1_TD$DIFF]. (G) Western blot quantification of a-SMA. Data were shown as fold change between injected and uninjected sides
f the penis. Data points were plotted as mean SEM (N = 3). [12_TD$DIFF]** p< [14_TD$DIFF]0.001, ** p< 0.001, *** p =0.0001 versus TGF-b1[10_TD$DIFF]-injected group[1_TD$DIFF]. (H) Western blot
uantification of a-SMA/Col I ratio. Data were shown as a ratio of fold change between injected and uninjected sides of the penis for a-SMA and Col I. Data
oints were plotted as mean SEM (N = 3). * p< [15_TD$DIFF]0.05, *** p = 0.0001, **** p < 0.0001 versus TGF-b1–injected group or in between groups. (I) Western blot
uantification of Col I/Col III ratio. Data were shown as a ratio of fold change between injected and uninjected sides of the penis for Col I and Col III. Data
oints were plotted as mean SEM (N = 3). * p< [16_TD$DIFF]0.05, ** p < 0.001 versus TGF-b1–injected group or in between groups. (J) Western blot quantification of
-SMA/Col III ratio. Data were shown as a ratio of fold change between injected and uninjected sides of the penis for a-SMA and Col III. Data points were
lotted as mean  SEM (N = 3). * p< [16_TD$DIFF]0.05, ** p< 0.001 versus TGF-b1–injected group or in between groups. a-SMA = alpha-smooth muscle actin;
ol = collagen; combined = TGF-b1 injected plus combined treatment group; MAP =mean arterial pressure; PD = Peyronie's disease; SEM = standard error of
e mean; tamoxifen = TGF-b1 injected + tamoxifen treatment group; TGF-b1 = transforming growth factor-b1; TGF-b1 = TGF-b1–injected group;
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Fig. 6 – Immunohistochemical staining for different treatment groups. Representative images of Masson's Trichrome staining and H&E staining in
whole sections of rat penis for (A) TGF-b1–injected group (left: Masson's Trichrome staining for injected side [4T magnification], right: H&E staining
for injected side (4T magnification)], (B) TGF-b1–injected group treated with vardenafil (left: Masson's Trichrome staining for injected side [4T
magnification], right: H&E staining for injected side [4T magnification]), (C) TGF-b1–injected group treated with tamoxifen (left: Masson's Trichrome
staining for injected side [4T magnification], right: H&E staining for injected side [4T magnification]), and (D) TGF-b1–injected group treated with the
combination of vardenafil and tamoxifen (left: Masson's Trichrome staining for injected side [4T magnification], right: H&E staining for injected side
[4T magnification]). The black arrow indicates smooth muscle, the orange circle indicates collagenous fibrotic plaque, and blue arrows indicate nuclei
(cellular infiltration due to inflammation). H&E = haematoxylin and eosin; TGF-b1 = transforming growth factor-b1.
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In contrast to the single-target approach, phenotypic
screening seeks to find compounds that target a pheno-
type rather than a single molecular target. In this case, we
have chosen transformation of fibroblasts to myofibro-blasts as the target phenotype and developed an assay that
can quantify inhibition of myofibroblast transformation in
a reproducible manner. Using this assay, we then tested
21 compounds/drugs that have been suggested as
potentially antifibrotic agents. Among this cohort, only
two groups were able to inhibit myofibroblast transfor-
EU RO P E AN URO LOGY 7 5 ( 2 019 ) 3 2 9 – 3 4 0338mation: PDE5i and SERMs. When applied together, these
two classes showed synergistic activity both in vitro and in
vivo.
To our knowledge, this is the first study to show a
synergy between PDE5i and SERMs. PDE5i have previously
been suggested to be effective antifibrotic agents in vitro
using TA-derived fibroblasts [22]. This was further
confirmed in an animal model for PD with long-term
vardenafil treatment [23,24]. Furthermore, in vivo studies
led to PDE5i being proposed as a potential treatment for
other fibrotic disorders such as muscle fibrosis in a
Duchenne muscular dystrophy mouse model [25], and
for the prevention of cardiac fibrosis and its underlying
cardiac fibroblast activation [26]. Tamoxifen has been
shown to be effective in animal models for renal
tubulointerstitial fibrosis and periportal hepatic fibrosis
[27,28]. The antimyofibroblast effect has also been
reported in models utilising TGF-b1–mediated activation
of primary human dermal and breast fibroblasts [29]. Pre-
vious research suggested that the effect of tamoxifen on
fibroblast-mediated collagen contraction is due either to
downregulation of TGF-b2 [30] or a change in the
morphology of fibroblasts [31]. Oestradiol has been shown
to inhibit transformation of TA-derived fibroblast to
myofibroblasts [32]. However, [40_TD$DIFF]no previous study has
investigated the effect of tamoxifen in an animal model
of PD.
Previous clinical studies have shownmixed results using
PDE5i and SERMs [33–37]. An open-label single-arm study
with tamoxifen showed a positive effect [33], while a later
placebo-controlled study showed no effect with tamoxifen
[34]. However, the open-label study noted that tamoxifen
showed some improvement in patients with early PD [33],
while all the patients in the latter study were in the late
phase of the disease [34]. Similarly, in studies with PDE5i,
the results have been mixed [35–37]. This is not surprising
since the drugs were tested on patients with established
plaque-fibrotic tissue. Our results suggest that PDE5i or
SERMs inhibit myofibroblast transformation and ECM
production; they would not be able to reverse the
established/preformed fibrosis. We are therefore proposing
that the combination of PDE5i and SERMs will inhibit
myofibroblast transformation, thereby leading to new
fibrosis formation, and prevent new plaque formation.
We believe that more and more men are presenting at
early stages of the disease, as there are now better
information resources and access to healthcare to have
symptoms investigated. Indeed, others have reported that
30–40% of patients presentwith progressing deformity [38–
40]. This drug combination may be more effective in
patients in the acute phasewhere penile pain or the onset of
a nodule would be an indication for referral. This will be an
area for patient and primary care education.
The doses of vardenafil and tamoxifen used in our animal
model are representative of their clinical doses: tamoxifen
20 mg twice daily and vardenafil 20 mg daily (please see the
Supplementary material that explains the rationale behind
the dose selection).This study is limited by not providing a mechanism of
action for the proposed synergistic effect of the drugs,
something that is currently being investigated. The number
of compounds/drugs that have been screened also limits the
study; other SERMs that are used in treatment of male
fertility would be very interesting to test. A larger
phenotypic screening campaign is planned, hopefully
providing us with more hits that might reveal new
treatment strategies not only for PD but also for fibrosis
in general.
Another limitation to the study is that the drugs were
tested in only one of the several animal PD models
[41]. Although TGF-b1 injection model is most widely
used, it may not necessarily be the most clinically relevant
animal model; for example, it does not develop curvature of
the penis. Further studies are required to test this
combination in other animal models of PD.5. Conclusions
In summary, this is the first study to demonstrate a
synergistic antifibrotic effect of a combination of PDE5i and
SERMs in in vitro and in vivo disease models. Future
prospective clinical trials using a combination of these
drugs should be considered during the active phase of PD,
given the early evidence of benefit in both in vitro and in
vivo models. We also envisage that the combination will be
more efficacious than using either of the drugs as a
monotherapy. We will be investigating such a combination
in men with early PD in the near future. These results are
likely to lead to further research into the interaction
between the two pathways and development of novel
therapeutic approaches for the prevention and/or treat-
ment of other fibrotic diseases.
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